MERZ-AESTHETICS

3.6.2022 09:02:06 CEST | Business Wire | Press release

Merz Aesthetics presents data at the IMCAS World Congress 2022

Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 2022 International Master Course on Aging Science (IMCAS) World Congress, with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diversifying society and a younger patient base. IMCAS, held from Friday, June 3 to Sunday, June 5, 2022, will take place in a hybrid format, enabling participants to attend the conference in person in Paris and/or virtually. Merz Aesthetics is a diamond sponsor of the global industry congress.

“This year’s IMCAS Congress is an opportunity to reunite with our partners and leading experts in dermatology, plastic surgery and aging science to bridge our respective fields and drive innovation in aesthetic medicine forward,” said Frank Brandt-Pollmann, President EMEA, Merz Aesthetics. “We exist to fuel confidence by helping people look better, feel better and live better, and we’re proud to present research across our portfolio that reinforces the need for diverse and expansive experiences for every patient.”

Merz Aesthetics continues to embrace the diversified and unique needs of aesthetic patients and practitioners, recognizing the personal journey for each patient and partnering with experts to meet those needs. As patients are starting their aesthetic journey earlier in their lives, Merz Aesthetics stands for a long term and responsible view on how patients are treated.

Merz Aesthetics is organizing a program led by esteemed medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the course of the meeting.

Merz Aesthetics Symposium #Beautification – Embracing #Uniqueness, Advanced aesthetic strategies for the needs of diverse generations – Dr. Gabriela Casabona, Dr. Daria Voropai, Dr. Raj Aquilla, Sunday, June 5, 2022 | 10:30 – 12:30h CEST
Merz Aesthetics support of IMCAS Cadaver Workshop with anatomist Prof. Dr. Thilo Schenck and Live Injector: Dr. Fouad Belfkira - Friday, June 3, 2022 10:30 – 11:00h CEST
Product Analysis Session “Emerging Toxins”, Andy Curry, Assoc. Med. Director, Merz Aesthetics - Friday, June 3, 2022, 8:30 - 12:00 h CEST
Innovation Tank, Dr. Samantha Kerr, CSO, Merz Aesthetics, Friday, June 3, 2022, 8:30 -12:00h CEST
IMCAS Economic Tribune Round Table, Bob Rhatigan, CEO Merz Aesthetics, Saturday, June 4, 2022, 16:00 – 18:00h CEST

E-Poster Presentations

Virtual posters will be available for viewing on site for the duration of the congress and displayed on the virtual E-poster platform with detailed abstracts.

Botulinum Toxin

Study Design of LONG RUN: A longitudinal evaluation and real-world evidence of uniquely purified incobotulinumtoxinA in treatment naïve participants. Presenting author: Andy Curry , Merz Aesthetics – USA, Terrence Keaney, MD – USA, Karyn Siemasko, PhD -USA

IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines: Final Study Results. Martina Kerscher, MD PhD – Germany, Sabrina Fabi, Md – USA, Tanja Fischer, MD PhD – Germany, Presenting author: Michael Gold, MD – USA, John Joseph, MD – USA, Welf Prager, MD – Germany, Berthold Rzany, MD ScM – Germany, Steve Yoelin, MD – USA, Susanna Roll, PhD – Germany, Gudrun Klein, PhD – Germany, Corey Maas, MD PhD – USA.

Belotero^® and Radiesse^®

A Hybrid Filler: Combining Calcium Hydroxylapatite and Hyaluronic Acid Fillers for Aesthetic Indications, Presenting author: Jonathan Kadouch , MD, PhD – Netherlands, Nabil Fakih-Gomez, MD-Lebanon.

Comparative Histomorphological Evaluation of the Injectable Cohesive Polydensified Matrix Hyaluronic Acid and Calcium Hydroxylapatite Combination. Presenting author: Yana Yutskovskaya , MD – Russia, Evgenia Kogan, MD PhD – Russia, Alla Y Koroleva, MD – Russia.

Technical evaluation and comparison of calcium hydroxylapatite (CaHA) containing dermal fillers, Sarah Backfisch, Radia El-Banna, Presenting author: Cleiton Kunzler , Roland Stragies, and Nadine Hagedorn, Merz Aesthetics GmbH – Germany.

Increased hyaluronic acid concentration enhances the local tissue lifting capacity in an ex vivo human skin model, Kay Marquardt, Christian Hartmann, Christina Wollenburg, Tristan Gesing, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.

Animal study indicates importance of distance between microspheres for neocollagenesis, Bartosch Nowag, Nils Warfving, Presenting author: Thomas Hengl, Merz Aesthetics GmbH – Germany.

About Merz Aesthetics

Merz Aesthetics is a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence. We aim to help people around the world look, feel and live like the best versions of themselves—however they define it. Clinically proven, our product portfolio includes injectables, devices and skin care treatments designed to meet each patient’s needs with high standards of safety and efficacy. We are known for building unique connections with customers who feel like family. Our global headquarters is in Raleigh, N.C., USA, with a commercial presence in 36 countries worldwide. Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany. Learn more at merzaesthetics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220603005010/en/

About Business Wire

Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release

Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind

Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release

Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath

De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release

The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par

Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release

Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr

Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release

Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom